What’s Next for Comprehensive Genomic Profiling in Cancer Care
July 10th 2025An expert discusses how comprehensive genomic profiling will continue growing as an essential component of personalized cancer care, expanding into serial testing for resistance monitoring, tumor burden tracking, and potentially earlier-stage cancers as targeted therapies prove effective beyond advanced disease.
Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
July 10th 2025An expert discusses how education about the clinical impact of genomic testing, understanding of targeted therapies, turnaround times, and team-based approaches are essential to bridge the gap in routine comprehensive genomic profiling adoption.
Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
July 10th 2025An expert discusses how molecular profiling has become essential for most solid tumor cancers, particularly in lung cancer, where both tissue- and plasma-based testing using next-generation sequencing help identify actionable genomic targets and monitor resistance patterns.
Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
July 10th 2025An expert discusses how molecular profiling has become essential for most solid tumor cancers, particularly in lung cancer, where both tissue- and plasma-based testing using next-generation sequencing help identify actionable genomic targets and monitor resistance patterns.
CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies
July 9th 2025Panelists discuss how improving CAR T accessibility through reduced monitoring requirements could strengthen its position against bispecific antibodies in treatment decision-making, emphasizing that access considerations should only influence therapy choice when efficacy and safety are comparable, not when CAR T demonstrates superior outcomes.
Looking Ahead in HER2+ mBC: Unmet Needs, Future Perspectives and Highlights From ASCO 2025
July 8th 2025Panelists highlighted the impressive central nervous system activity of trastuzumab deruxtecan demonstrated in the DX12 trial, underscoring the need for multidisciplinary collaboration to optimize treatment of brain metastases and reduce reliance on whole-brain radiation, while acknowledging ongoing challenges in sequencing and patient selection amid evolving therapies.
Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
July 8th 2025Panelists discuss how successful outpatient bispecific therapy requires robust infrastructure, including 24-hour monitoring capabilities, emergency department coordination, and liberal use of supportive medications.
Expert Insights: Later-Line Treatment Strategies for HER2+ Metastatic Breast Cancer
July 8th 2025Panelists agreed that beyond third-line therapy for HER2-positive metastatic breast cancer, treatment becomes highly individualized—often described as the “wild West”—with options including various monoclonal antibodies, tyrosine kinase inhibitors, chemotherapy, and emerging agents; decisions are largely based on prior toxicities, patient preferences, and disease biology, with clinical trials playing a crucial role in offering promising new therapies that may outperform standard care.
Debate: Sequencing Therapies for LR-MDS: ESA First vs Luspatercept First
July 8th 2025Panelists discuss the sequencing of therapies in lower-risk myelodysplastic syndromes, debating whether to initiate treatment with erythropoiesis-stimulating agents due to cost and patient variability or with luspatercept for its superior efficacy and potential disease-modifying effects, while highlighting ongoing trials exploring combined or sequential strategies.
Tucatinib Triplet Therapy: Efficacy, Safety and Clinical Decision-Making
July 8th 2025Panelists highlighted that the HER2CLIMB study showed adding tucatinib to trastuzumab and capecitabine provides a meaningful progression-free survival benefit in HER2-positive metastatic breast cancer with brain metastases, balancing improved intracranial control against manageable toxicities like diarrhea and hand-foot syndrome, and underscored the importance of patient education and dose management to maintain adherence and quality of life.
Debate: Inflection Point for LR-MDS Therapy: Serum EPO >200 U/L vs Serum EPO >500 U/L
July 8th 2025Panelists discuss treatment strategies for lower-risk myelodysplastic syndromes guided by serum erythropoietin (EPO) levels, weighing the reduced efficacy of erythropoiesis-stimulating agents at higher EPO levels against newer therapies’ benefits and challenges, and emphasizing personalized sequencing based on patient and disease characteristics.
Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
July 7th 2025Panelists discuss the critical role of sequencing B-cell maturation antigen (BCMA)-targeted therapies in multiple myeloma, emphasizing that administering chimeric antigen receptor (CAR) T-cell therapy before bispecific antibodies leads to better outcomes, while real-world evidence and emerging guidelines increasingly inform strategic decisions based on treatment timing, disease urgency, and patient-specific factors.
PERSEUS Trial: Design/Baseline Characteristics
July 7th 2025Panelists discuss the Perseus study, which compared daratumumab-based quadruplet therapy (Dara-VRD) with VRD alone in patients with newly diagnosed, transplant-eligible multiple myeloma, highlighting its focus on a generally fit population and demonstrating improved progression-free survival and deeper responses with the 4-drug regimen, while noting some limitations in applicability to patients with significant comorbidities.
Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
July 7th 2025Panelists discuss the emerging real-world use of talquetamab as a bridging therapy before chimeric antigen receptor (CAR) T-cell treatment in patients with advanced multiple myeloma, highlighting its ability to rapidly reduce tumor burden and improve CAR T outcomes despite unique toxicities and emphasizing how clinician-driven innovation is shaping practice ahead of clinical trial data.
Expert Opinion on Modern Availability of Several Agents
July 4th 2025Panelists discuss how the availability of multiple B-cell maturation antigen (BCMA) bispecific agents (with linvoseltamab approved in Europe and other agents in development) creates beneficial competition that could drive down costs and provide more treatment options, while acknowledging that safety and efficacy profiles appear comparable across agents, making accessibility and convenience key differentiating factors for patient care.